VKTXViking Therapeutics, Inc.

Nasdaq vikingtherapeutics.com


$ 50.49 $ -1.07 (-2.08 %)    

Wednesday, 03-Jul-2024 12:59:57 EDT
QQQ $ 490.95 $ 4.06 (0.83 %)
DIA $ 392.84 $ -0.46 (-0.12 %)
SPY $ 551.46 $ 2.45 (0.45 %)
TLT $ 91.86 $ 1.19 (1.31 %)
GLD $ 217.99 $ 2.43 (1.13 %)
$ 50.47
$ 52.10
$ 0.00 x 0
$ 50.54 x 246
$ 49.89 - $ 52.56
$ 8.28 - $ 99.41
1,635,676
na
5.22B
$ 1.27
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-25-2024 03-31-2024 10-Q
2 02-07-2024 12-31-2023 10-K
3 10-25-2023 09-30-2023 10-Q
4 07-26-2023 06-30-2023 10-Q
5 04-26-2023 03-31-2023 10-Q
6 02-10-2023 12-31-2022 10-K
7 10-26-2022 09-30-2022 10-Q
8 07-27-2022 06-30-2022 10-Q
9 04-27-2022 03-31-2022 10-Q
10 02-09-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 07-28-2021 06-30-2021 10-Q
13 04-28-2021 03-31-2021 10-Q
14 02-17-2021 12-31-2020 10-K
15 10-28-2020 09-30-2020 10-Q
16 07-29-2020 06-30-2020 10-Q
17 04-30-2020 03-31-2020 10-Q
18 02-26-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 08-01-2019 06-30-2019 10-Q
21 05-02-2019 03-31-2019 10-Q
22 03-13-2019 12-31-2018 10-K
23 11-07-2018 09-30-2018 10-Q
24 08-09-2018 06-30-2018 10-Q
25 05-09-2018 03-31-2018 10-Q
26 03-07-2018 12-31-2017 10-K
27 11-08-2017 09-30-2017 10-Q
28 08-09-2017 06-30-2017 10-Q
29 05-10-2017 03-31-2017 10-Q
30 03-21-2017 12-31-2016 10-K
31 11-10-2016 09-30-2016 10-Q
32 08-11-2016 06-30-2016 10-Q
33 05-10-2016 03-31-2016 10-Q
34 03-08-2016 12-31-2015 10-K
35 11-05-2015 09-30-2015 10-Q
36 08-14-2015 06-30-2015 10-Q
37 06-12-2015 03-31-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 sp-500-nasdaq-100-climb-to-record-highs-as-data-fosters-rate-cut-optimism-ahead-of-fed-minutes-gold-bonds-rally-whats-driving-markets-wednesday

The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for...

 morgan-stanley-initiates-coverage-on-viking-therapeutics-with-overweight-rating-announces-price-target-of-105

Morgan Stanley analyst Michael Ulz initiates coverage on Viking Therapeutics (NASDAQ:VKTX) with a Overweight rating and anno...

 hc-wainwright--co-reiterates-buy-on-viking-therapeutics-maintains-90-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ:VKTX) with a Buy and maintains $90 p...

 viking-therapeutics-unveils-results-for-obesity-treatment-at-ada-scientific-sessions

Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of nove...

 truist-securities-maintains-buy-on-viking-therapeutics-maintains-120-price-target

Truist Securities analyst Joon Lee maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and maintains $120 price target.

 whats-going-on-with-fattly-liver-disease-focused-madrigal-pharmaceuticals-sagimet-biosciences-shares-on-wednesday

Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress ...

 raymond-james-reiterates-strong-buy-on-viking-therapeutics

Raymond James analyst Steven Seedhouse reiterates Viking Therapeutics (NASDAQ:VKTX) with a Strong Buy.

 maxim-group-reiterates-buy-on-viking-therapeutics-maintains-120-price-target

Maxim Group analyst Naz Rahman reiterates Viking Therapeutics (NASDAQ:VKTX) with a Buy and maintains $120 price target.

 whats-going-on-with-viking-therapeutics-stock-on-tuesday

Viking Therapeutics reports promising 52-week data from its Phase 2b VOYAGE study on VK2809 for NASH.

 hc-wainwright--co-reiterates-buy-on-viking-therapeutics-maintains-90-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ:VKTX) with a Buy and maintains $90 p...